Volume | 15,524 |
|
|||||
News | - | ||||||
Day High | 1.048 | Low High |
|||||
Day Low | 1.0165 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Zentek Ltd | ZTEK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.02 | 1.0165 | 1.048 | 1.0199 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
103 | 15,524 | $ 1.03 | $ 16,033 | - | 0.974999 - 1.7494 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:49:49 | 5 | $ 1.035 | USD |
Zentek Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
140.14M | 100.82M | - | 73k | -14.41M | -0.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Zentek News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ZTEK Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.09 | 1.16 | 1.00 | 1.04 | 22,087 | -0.055 | -5.05% |
1 Month | 1.25 | 1.25 | 1.00 | 1.10 | 18,263 | -0.215 | -17.20% |
3 Months | 1.43 | 1.4591 | 1.00 | 1.21 | 19,798 | -0.395 | -27.62% |
6 Months | 1.28 | 1.59 | 0.974999 | 1.21 | 22,461 | -0.245 | -19.14% |
1 Year | 1.49 | 1.7494 | 0.974999 | 1.32 | 21,328 | -0.455 | -30.54% |
3 Years | 3.00 | 3.78 | 0.974999 | 2.54 | 55,357 | -1.97 | -65.50% |
5 Years | 3.00 | 3.78 | 0.974999 | 2.54 | 55,357 | -1.97 | -65.50% |
Zentek Description
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment.?It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19,?and the potential to use?similar?compounds?as pharmaceutical products?against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology. |